Device Week, 25 June 2021 – Major SPAC; Novel Heart Pump; And Breakthrough Device Designation
In this edition of Device Week, Medtech Insight's UK-based reporter Barnaby Pickering provides an insight into Procyrion’s novel device for decongesting cardiorenal syndrome patients. US Commercial and R&D manager, Reed Miller, highlights details on Pear Therapeutics’ recent SPAC acquisition, and managing editor, Marion Webb, discusses two companies that received types of approval for novel devices.
You may also be interested in...
As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date.
The UK-based company said it will use the new funding to advance commercialization of its daytime treatment for mild sleep apnea and snoring.
Babson recently raised $31m to accelerate commercialization of its blood testing “ecosystem,” developed with help from Siemens Healthineers and Becton Dickinson.